Data Mine: Treating Cancer
Cancer is the second-leading cause of death in the United States, surpassed only by heart disease. But recent technological developments offer the hope of new and better ways to combat the disease.
For many of the most pervasive types of cancer, about half of the drug candidates furthest along in the research pipeline use approaches other than that of traditional cytotoxic drugs, which work by killing cells or preventing their division.
With continuing advances in the development of therapies like monoclonal antibodies and tumor vaccines, biotechnology should account for a growing portion of the cancer drug market, which may reach $80 billion a year by 2009.
As costs soar and reimbursement wanes, though, many patients are unlikely to reap the benefits of some of the most promising of these developments.
Keep Reading
Most Popular
DeepMind’s cofounder: Generative AI is just a phase. What’s next is interactive AI.
“This is a profound moment in the history of technology,” says Mustafa Suleyman.
What to know about this autumn’s covid vaccines
New variants will pose a challenge, but early signs suggest the shots will still boost antibody responses.
Human-plus-AI solutions mitigate security threats
With the right human oversight, emerging technologies like artificial intelligence can help keep business and customer data secure
Next slide, please: A brief history of the corporate presentation
From million-dollar slide shows to Steve Jobs’s introduction of the iPhone, a bit of show business never hurt plain old business.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.